Der Onkologe

, Volume 15, Issue 5, pp 519–525 | Cite as

Asiatische Heilpilze

In der Diskussion: Komplementäre Onkologie
First Online:

Zusammenfassung

Asiatische Heilpilze enthalten komplexe Kohlenhydratverbindungen, die immunmodulierende Eigenschaften besitzen. Experimentelle Daten sprechen sowohl für direkte als auch indirekte Wirkungen auf Tumorzellen. Viel versprechende präklinische Daten belegen eine antitumorale Wirkung bei verschiedenen Tumorarten. In klinischen Studien wurden die alleinige Wirkung der Pilze und die Kombination mit Zytostatika geprüft. Die bisher vorliegenden Studiendaten sind unter wissenschaftlichen Gesichtspunkten nicht ausreichend, um einen therapeutischen Einsatz außerhalb von Studien zu befürworten. Patienten sollten über mögliche Nebenwirkungen und Kontaminationen von Präparaten informiert werden.

Schlüsselwörter

Heilpilze Ganoderma Lentinus Coriolus Agaricus 

Asian medical mushrooms

Abstract

Medical mushrooms from Asia contain complex polysaccharides with immunomodulating properties. Experimental data give evidence for both direct and indirect action on targets of tumor cells, and preclinical data show promising effects on different tumor types. In clinical studies, the effect of medical mushrooms was tested, both as the single agent and in combination with chemotherapy. From a scientific point of view, published data are not yet conclusive, and medical mushrooms should not be used outside of studies. Patients should know putative side effects and should be informed about putative contamination of the products.

keywords

Medical mushrooms Reishi (Ganoderma lucidum) Lentinus Coriolus Agaricus 
This is a preview of subscription content, log in to check access.

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Ehlers S (2003) Chinesische Heilpilze. Haug, StuttgartGoogle Scholar
  2. 2.
    Lelley J (1997) Die Heilkraft der Pilze – Gesund durch Mykotherapie. Econ Taschenbuch, MünchenGoogle Scholar
  3. 3.
    Ehlers S (2005) Mykotherapie - Heilbehandlung mit Pilzen. In Ratgeber unkonventionelle Krebstherapien. Edited by Münstedt K. ecomed Medizin, Lansberg/Lech 301–306Google Scholar
  4. 4.
    Wasser SP (2002) Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 60:258–274PubMedCrossRefGoogle Scholar
  5. 5.
    Ooi VE, Liu F (2000) Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem 7:715–729PubMedGoogle Scholar
  6. 6.
    Akramiene D, Kondrotas A, Didziapetriene J, Kevelaitis E (2007) Effects of beta-glucans on the immune system. Medicina (Kaunas) 43:597–606Google Scholar
  7. 7.
    Borchers AT, Stern JS, Hackman RM et al (1999) Mushrooms, tumors, and immunity. Proc Soc Exp Biol Med 221:281–293PubMedCrossRefGoogle Scholar
  8. 8.
    Chen J, Seviour R (2007) Medicinal importance of fungal beta-(1→3), (1→6)-glucans. Mycol Res 111:635–652PubMedCrossRefGoogle Scholar
  9. 9.
    Büssing A (2008) Pharmakologische Hinweise zur Anwendung von Ganoderma lucidum bei Tumorerkrankungen. Dtsch Zeitschrift Onkol 40:62–65CrossRefGoogle Scholar
  10. 10.
    Boh B, Berovic M, Zhang J, Zhi-Bin L (2007) Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 13:265–301PubMedCrossRefGoogle Scholar
  11. 11.
    Sliva D (2003) Ganoderma lucidum (Reishi) in cancer treatment. Integr Cancer Ther 2:358–364PubMedCrossRefGoogle Scholar
  12. 12.
    Lin ZB, Zhang HN (2004) Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms. Acta Pharmacol Sin 25:1387–1395PubMedGoogle Scholar
  13. 13.
    Jiang J, Slivova V, Sliva D (2006) Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. Int J Oncol 29:695–703PubMedGoogle Scholar
  14. 14.
    Zaidman BZ, Wasser SP, Nevo E, Mahajna J (2007) Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells. Int J Oncol 31:959–967PubMedGoogle Scholar
  15. 15.
    Zaidman BZ, Wasser SP, Nevo E, Mahajna J (2008) Coprinus comatus and Ganoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells. Mol Biol Rep 35:107–117PubMedCrossRefGoogle Scholar
  16. 16.
    Liu J, Shimizu K, Konishi F et al (2007) The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum. Bioorg Med Chem 15:4966–4972PubMedCrossRefGoogle Scholar
  17. 17.
    Stanley G, Harvey K, Slivova V et al (2005) Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells. Biochem Biophys Res Commun 330:46–52PubMedCrossRefGoogle Scholar
  18. 18.
    Nonaka Y, Shibata H, Nakai M et al (2006) Anti-tumor activities of the antlered form of Ganoderma lucidum in allogeneic and syngeneic tumor-bearing mice. Biosci Biotechnol Biochem 70:2028–2034PubMedCrossRefGoogle Scholar
  19. 19.
    Yao PY, Gao ZM, Fang ST, Ke L (n d) Evaluation of the subsidiaryeffects of taking PSP orally on the chemotherapy of stomach cancer. Shanghai 269–270Google Scholar
  20. 20.
    Yang QY, Wang MM (n d) The effect of ganoderma lucidum extract against fatigue and endurance in the absence of oxygen. Taipe 101–113Google Scholar
  21. 21.
    Chen X, Hu ZP, Yang XX et al (2006) Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. Int Immunopharmacol 6:499–508PubMedCrossRefGoogle Scholar
  22. 22.
    Gao Y, Tang W, Dai X et al (2005) Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. J Med Food 8:159–168PubMedCrossRefGoogle Scholar
  23. 23.
    Gao Y, Zhou S, Jiang W et al (2003) Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest 32:201–215PubMedCrossRefGoogle Scholar
  24. 24.
    Kwok Y, Ng KF, Li CC et al (2005) A prospective, randomized, double-blind, placebo-controlled study of the platelet and global hemostatic effects of Ganoderma lucidum (Ling-Zhi) in healthy volunteers. Anesth Analg 101:423–426, tablePubMedCrossRefGoogle Scholar
  25. 25.
    Wachtel-Galor S, Tomlinson B, Benzie IF (2004) Ganoderma lucidum („Lingzhi“), a Chinese medicinal mushroom: Biomarker responses in a controlled human supplementation study. Br J Nutr 91:263–269PubMedCrossRefGoogle Scholar
  26. 26.
    Yuen JW, Gohel MD (2005) Anticancer effects of Ganoderma lucidum: A review of scientific evidence. Nutr Cancer 53:11–17PubMedCrossRefGoogle Scholar
  27. 27.
    Nakano H, Namatame K, Nemoto H et al (1999) A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: Effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group. Hepatogastroenterology 46:2662–2668PubMedGoogle Scholar
  28. 28.
    Taguchi T (1987) Clinical efficacy of lentinan on patients with stomach cancer: End point results of a four-year follow-up survey. Cancer Detect Prev Suppl 1:333–349PubMedGoogle Scholar
  29. 29.
    Tari K, Satake I, Nakagomi K et al (1994) Effect of lentinan for advanced prostate carcinoma. Hinyokika Kiyo 40:119–123PubMedGoogle Scholar
  30. 30.
    Wakui A, Kasai M, Konno K et al (1986) Randomized study of lentinan on patients with advanced gastric and colorectal cancer. Tohoku Lentinan Study Group. Gan To Kagaku Ryoho 13:1050–1059PubMedGoogle Scholar
  31. 31.
    Taguchi T, Furue H, Kimura T et al (1985) Results of phase III study of lentinan. Gan To Kagaku Ryoho 12:366–378PubMedGoogle Scholar
  32. 32.
    Fisher M, Yang LX (2002) Anticancer effects and mechanisms of polysaccharide-K (PSK): Implications of cancer immunotherapy. Anticancer Res 22:1737–1754PubMedGoogle Scholar
  33. 33.
    Ng TB (1998) A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol 30:1–4PubMedGoogle Scholar
  34. 34.
    Niimoto M, Hattori T, Tamada R et al (1988) Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg 18:681–686PubMedCrossRefGoogle Scholar
  35. 35.
    Nakazato H, Koike A, Ichihashi H et al (1989) An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)--a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer. Gan To Kagaku Ryoho 16:2563–2576PubMedGoogle Scholar
  36. 36.
    Mitomi T, Kyoji O (1986) Clinical study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer. Gan To Kagaku Ryoho 13:2532–2537PubMedGoogle Scholar
  37. 37.
    Nakajima T, Inokuchi K, Hattori T et al (1989) Multi-institutional cooperative study of adjuvant immunochemotherapy in gastric cancer--five-year survival rate. Gan To Kagaku Ryoho 16:799–806PubMedGoogle Scholar
  38. 38.
    Sakamoto J, Nakazato H (1993) Evaluation of adjuvant immunochemotherapy in advanced gastric cancer. Gan To Kagaku Ryoho 20:2525–2530PubMedGoogle Scholar
  39. 39.
    Ito I, Mukai M, Ninomiya H et al (2008) Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage II colorectal cancer. Oncol Rep 20:1189–1194PubMedGoogle Scholar
  40. 40.
    Ito I, Mukai M, Ninomiya H et al (2008) Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage III colorectal cancer. Oncol Rep 20:1521–1526PubMedGoogle Scholar
  41. 41.
    Sakai T, Yamashita Y, Maekawa T et al (2008) Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer. Cancer Biother Radiopharm 23:461–467PubMedCrossRefGoogle Scholar
  42. 42.
    Ishibashi K, Ishiguro T, Kuwabara K et al (2008) Administration of polysaccharide K (PSK) for stage III colorectal cancer in clinical practice. Gan To Kagaku Ryoho 35:2283–2285PubMedGoogle Scholar
  43. 43.
    Sakamoto J, Morita S, Oba K et al (2006) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 55:404–411PubMedCrossRefGoogle Scholar
  44. 44.
    Nishiwaki Y, Furuse K, Fukuoka M et al (1990) A randomized controlled study of PSK combined immuno-chemotherapy for adenocarcinoma of the lung. The Advanced Lung Cancer Immuno-chemotherapy Study Group. Gan To Kagaku Ryoho 17:131–136PubMedGoogle Scholar
  45. 45.
    Cassileth BR, Lucarelli CD (2003) Herb-Drug Interactions in Oncology. B.C. Decker Inc, LondonGoogle Scholar
  46. 46.
    Ernst E, Pittler MH, Wider B (2006) The desktop guide to complementary and alternative medicine. An evidence-based approach. Mosby ElsevierGoogle Scholar
  47. 47.
    Nakatsugawa M, Takahashi H, Takezawa C et al (2003) Hericium erinaceum (yamabushitake) extract-induced acute respiratory distress syndrome monitored by serum surfactant proteins. Intern Med 42:1219–1222PubMedCrossRefGoogle Scholar
  48. 48.
    Nakamura T (1992) Shiitake (Lentinus edodes) dermatitis. Contact Dermatitis 27:65–70PubMedCrossRefGoogle Scholar
  49. 49.
    Hanada K, Hashimoto I (1998) Flagellate mushroom (Shiitake) dermatitis and photosensitivity. Dermatology 197:255–257PubMedCrossRefGoogle Scholar
  50. 50.
    Levy AM, Kita H, Phillips SF et al (1998) Eosinophilia and gastrointestinal symptoms after ingestion of shiitake mushrooms. J Allergy Clin Immunol 101:613–620PubMedCrossRefGoogle Scholar
  51. 51.
    Kai N, Ishii H, Iwata A et al (2008) Chronic hypersensitivity pneumonitis induced by Shiitake mushroom cultivation: Case report and review of literature. Nihon Kokyuki Gakkai Zasshi 46:411–415PubMedGoogle Scholar
  52. 52.
    Bundesinstitut für Risikobewertung (BfR) (2004) Gesundheitliches Risiko von Shiitake-Pilzen. Stellungnahme des BfR vom 23. Juni 2004Stellungnahme des BfR vom 1–7 2004Google Scholar

Copyright information

© Springer Medizin Verlag 2009

Authors and Affiliations

  1. 1.Medizintheorie und KomplementärmedizinUniversität Witten/HerdeckeHerdeckeDeutschland
  2. 2.Onkologische AbteilungHabichtswald-Klinik KasselKasselDeutschland

Personalised recommendations